MYH7 mutations are found in approximately 20% of hypertrophic cardiomyopathy (HCM) patients. Currently, mutational analysis is based on the sequencing of the coding exons and a few exon-flanking intronic nucleotides resulting in omission of single exon deletions and mutations in internal intronic, promoter, and 3´UTR regions. We amplified and sequenced large MYH7 fragments in 60 HCM patients without a previously identified sarcomere mutation. Lack of aberrant PCR-fragments excluded single exon deletions from the patients. Instead, we identified several new rare intronic
Abstract.
MYH7 mutations are found in approximately 20% of hypertrophic cardiomyopathy (HCM) patients. Currently, mutational analysis is based on the sequencing of the coding exons and a few exon-flanking intronic nucleotides resulting in omission of single exon deletions and mutations in internal intronic, promoter, and 3´UTR regions. We amplified and sequenced large MYH7 fragments in 60 HCM patients without a previously identified sarcomere mutation. Lack of aberrant PCR-fragments excluded single exon deletions from the patients. Instead, we identified several new rare intronic
variants. An intron 26 single nucleotide insertion (-5 insC) was predicted to affect premRNA splicing, but allele frequencies did not differ between patients and controls (n=150). We found several rare promoter variants in the patients compared to the controls, some of which were in binding sites for transcription factors, and could thus affect gene expression. Only one rare 3´UTR variant (c.*29T>C) found in the patients was absent among the controls. This nucleotide change would not affect the binding of known micro-RNAs. Therefore, MYH7 mutations outside the coding exon sequences would be rarely found among HCM patients. However, changes in the promoter region could be linked to the risk of developing HCM. Further research to define the functional effect of these variants on gene expression should be necessary to confirm the role of the MYH7 promoter on cardiac hypertrophy.
Introduction.
Hypertrophic cardiomyopathy (HCM) is the essential form of left-ventricular hypertrophy (LVH), in which the hypertrophy is not secondary to hypertension, exercise, cardiac valvular disease, or any other condition that could result in the development of LVH (1, 2) . HCM is the most common cause of sudden cardiac death (SCD) at young age and a major cause of morbidity and mortality in the elderly. HCM is frequently familial and inherited as a mendelian dominant disease caused by mutations in sarcomeric genes (3) . The clinical course is variable, ranging from severe incapacitating symptoms to no symptoms at all. A gene/mutation effect has been proposed to explain the clinical heterogeneity, although the existence of a genotypephenotype correlation remains controversial (4, 5) . According to most studies, approximately 50% of the HCM cases would have mutations in the genes encoding the cardiac myosin-binding protein C3 (MYBPC3) or the cardiac heavy chain beta-myosin (MYH7), while other genes are mutated in <10% of the patients (6) (7) (8) (9) (10) (11) (12) . Mutations in MYH7 would be more frequent in severe forms of hypertrophy and in patients with a family history of HCM/SCD (13).
The current genetic tests for HCM rely in the analysis of candidate genes for the coding exons (missense/nonsense and frameshifting mutations) and a few bases of the flanking introns (splicing mutations). This search for "classical" mutations would fail to identify mutations in a significant number of patients, mainly sporadic cases without a clear family history of HCM/SCD (4, 13) . The imperfect yield of the genetic testing could be explained in part by the existence of not yet identified HCM-genes, but is also possible that "non-classical" mutations in known HCM-genes (i.e. mutations in deep intronic, promoter, and 3´ untranslated nucleotides, and large gene rearrangements) could also explain the disease in some patients (14) (15) (16) (17) . Our aim was to determine whether nucleotide changes in the promoter region, the internal intronic sequence, and the 3´ untranslated region (UTR) of the MYH7 gene could be linked to HCM in some cases.
For this purpose, we amplified and sequenced the full MYH7 gene (including the proximal promoter region) in a cohort of HCM patients negative for sarcomeric mutations.
PATIENTS AND METHODS

Patients.
The study involved a total of 150 HCM non-related index cases, recruited through the Cardiology Department of Hospital Universitario Central Asturias (HUCA) in the period 2001-2010 ( Table 1) . HCM was diagnosed based on clinical symptoms and the presence of a left ventricular septum (LVS) >15 mm in the absence of any other condition that could explain the hypertrophy. Familial HCM was defined as the existence of at least one relative also diagnosed with HCM or SCD. In patients without a recognized family history of HCM, echocardiographic examination was performed on the parents when possible. Cases with one parent who had a LVS>15 mm were also classified as familial HCM.
The controls were 150 healthy individuals aged 50-75 years (mean age 58 ± 15; 55% male), recruited through the Blood Bank and the Cardiology Department of HUCA.
They did not have symptoms of cardiovascular disease, but none was echocardiographically evaluated to exclude the presence of asymptomatic LVH.
All the patients and controls were Caucasians from the regions of Asturias (Northern Spain) and gave their informed consent to participate in the study, approved by the Ethical Committee of HUCA.
Sarcomeric genes mutation analysis
The coding exons of the MYH7, MYBPC3, TNNT2, TNNI3, TPM1, TNNC3, MYL2, and MYL3 genes were polymerase chain reaction (PCR) amplified and sequenced in the 150 patients, as part of the routine work of the HUCA -Molecular Genetics Laboratory.
The mutation analysis of most of these cases was previously reported (9, 13, 18) .
Briefly, the exons were amplified with primers that matched the flanking introns and the PCR products (all <600 bp long) were purified and sequenced using BigDye chemistry in an ABI3130xl system (www. appliedbiosystems.org). Patient´s sequences were compared with the reference sequences in the Ensembl database (www.ensembl.org).
Mutations reported in the Cardiogenomics database (www.cardiogenomics.org) were considered bona fide mutations. New nucleotide changes were considered mutations based on their putative effect on the protein sequence. For missense changes we also confirmed their absence in the controls and the amino acid conservation between species.
MYH7 long range amplification and resequencing
In all the patients we amplified the whole MYH7 gene (approximately 26 kb) in 23 large overlapping fragments (supplementary figure 1 at http://jmd.amjpathol.org).
These were 890 to 2,250 bp PCR-fragments generated with primers that matched introns (table 2). The PCR primers contained 5´clamping artificial sequences to simplify the sequencing process by using the same forward and reverse sequencing primers.
To define new MYH7 mutations outside the exon and intron flanking regions, the whole PCR fragments of 60 patients without sarcomeric mutations (30 familial and 30 sporadic cases) were purified and sequenced in approximately 600 bp long reads. In addition to the clamping sequencing primers we used internal primers (primers and sequencing conditions are available upon request to the corresponding author). All the nucleotide changes were classified as MYH7 polymorphisms when they were reported in the Ensembl database (MYH7 reference sequence: ENSG00000092054).
MYH7 variants genotyping and bioinformatic analysis
All the intronic nucleotide changes found in the 60 patients and non-previously reported as MYH7 polymorphisms were also determined in the 150 controls through restriction enzyme digestion of a PCR fragment (PCR-RFLP) or single strand conformation analysis (SSCA; experimental procedure available upon request) (9, 19) . Briefly, fragments 301 to 416 bp long were amplified. Three µl were mixed with 17 µl of formamide and denatured at 95°C for 2 min. Seven µl were then loaded on 12% polyacrylamide gels (29:1 acrylamide:bisacrylamide; 30 cm length) and electrophoresed at room temperature and 5 W for 18 hours. Gels were silver stained to visualize the electrophoretic pattern of each sample. The putative effect on pre-mRNA splicing of the intron changes which frequency differed between patients and controls was determined online with the Splice Site Prediction by Neural Network (http://www.fruitfly.org/seq_tools/splice.html).
We also genotyped all the patients and controls for the exon 8 (rs2069542) and intron 26 variant (-5insC) through a PCR-RFLP method (supplementary figure 2 at http://jmd.amjpathol.org).
MYH7 promoter and 3´ UTR analysis
The 3´ UTR (exon 40) and promoter regions of the 150 HCM patients and 150 controls were PCR-amplified in 400 to 500 bp overlapping fragments (table 3). These fragments were subjected to SSCA and the fragments that showed heterogenous electrophoretic patterns were sequenced to identify the nucleotide changes. The putative effect of the promoter and 3´UTR variants on transcription factors (TFs) or microRNA (miRNAs) binding sites was determined online with the TFsearch (http://cbrc.jp/research/db/TFSEARCH.html) and miRbase (http://ebi.ac.uk/enrightsrv/microcosm) programs.
MYH7 transcript analysis in heart tissues
Heart tissue from five patients who underwent a cardiac transplant was obtained and total RNA was isolated (TRIZOL, Invitrogen, Carlsbad, CA). Two of them were familial HCM cases with MYH7 mutations (p.Val822Met and p.Arg453Cys). The RNAs were retrotranscribed (Qiagen, Hilden, Germany) and the cDNAs PCR-amplified with primers that matched MYH7 exons 2 and 10 (supplementary figure 3 at http://jmd.amjpathol.org). PCR fragments were purified and sequenced.
Statistical analysis.
The Chi-squared or Fisher Exact Probability tests were used to compare the allele and genotype frequencies between patients and controls. The large PCR products from 60 patients without a sarcomeric mutation were sequenced. In addition to the MYH7 exon and the proximal flanking intronic variants found in the routine search for mutations, we also identified a total of 59 nucleotide changes in distal intronic sequences. These were known polymorphisms (n=51), or new rare nucleotide changes (n=8) ( Table 5 ). The bioinformatic analysis showed that none of these rare changes would affect pre-mRNA splicing. In addition, genotype and allele frequencies for the common intron variants did not differ between patients and controls and all them were thus classified as likely non-pathological variants.
RESULTS
MYH7 long range amplification and sequencing
Promoter and 3´UTR variants
The proximal promoter and 3´UTR were analyzed in the 150 patients and controls through SSCA. We found a total of 10 promoter variants, six new rare variants not found among the controls ( Table 5 ). All these rare promoter changes were in sporadic cases. The bioinformatic analysis indicated that the less frequent allele of some of these promoter variants would eliminate or create binding sites for transcription factors such as NF-kB (-923 T>A), MyoD (-609 T>C), Nkx-2 (-537 C>T), and ADR1, STRE, MZF1
(-436 G>T). We found two nucleotide variants in the 3´ UTR. In addition to one previously reported polymorphism found in patients and controls, two patients were heterozygotes for a nucleotide change not found among the controls, c.*29T>C. A bioinformatic analysis indicated that this variant did not affect the seed sequence for known miRNAs. Genotype and allele frequencies for the common promoter and 3´UTR variants did not differ between patients and controls. The intron 26 -5 insC could also affect the pre-mRNA splicing and could thus have a pathogenic effect. None of the heart tissues carried the rare insC and we could thus not determine its effect on mRNA. However, allele frequencies did not differ between patients and controls suggesting a lack of effect on the risk of developing HCM (table   5) .
Discussion
The search for MYH7 mutations in HCM patients relies on the amplification and sequencing of PCR-fragments that contained a single exon and a few flanking intronic bases. In this way, mutations in internal intronic nucleotides or in the promoter and 3´UTR sequences could be missed. In addition, full single exon deletions would not be detected in case the PCR primers matched the deleted region (14) . To overcome this limitation, we amplified and sequenced large overlapping DNA fragments containing several exons. All the PCR-fragments were visualized as single electrophoretic bands,
suggesting that large deletions were absent among our HCM cases.
Intronic splicing mutations in sarcomeric genes have been reported in some HCM patients. Typically, these mutations are located in the five nucleotides immediately upstream/downstream of the exons. We found a rare MYH7 intron 26 -5insC polymorphism. Interestingly, the insertion allele was predicted to reduce the splicing score. Unfortunately none of the five heart tissues had the insertion allele and we could thus not determine its effect on splicing. However, the fact that the frequency of the -5 insC did not differ between patients and controls suggested a lack of effect on HCMrisk.
Internal intronic nucleotide changes that resulted in pre-mRNA splicing defects have been reported in some diseases (20) . We identified several internal MYH7 intron variants in our HCM patients, some of them not previously reported. A bioinformatic analysis showed that none of them would have an effect on pre-mRNA splicing. The presence of MYH7 alternative transcripts in cardiac tissue of patients with failing heart was recently reported (21) . Compared to cardiac tissue from healthy donors, several sarcomeric mRNAs exhibited increased intron retention in diseased myocardium. In the case of MYH7 two transcripts retaining introns 4 (MYH7-1) and 5 (MYH7-2) were observed.
Intron retention can be caused by either exon and intron nucleotide variants, and results
in transcripts containing premature stop codons that are subjected to nonsense-mediated decay or translated as aberrant protein sequences (22-24). We could not explore the effect of the rare intronic changes because no heart tissue was available from the patients who carried these alleles.
All the nucleotide variants found in the MYH7 coding exons were previously reported, and would result in either silent or missense amino acid changes (p.S1491C). They would thus not have a pathogenic effect. The common SNP rs2069542 (silent for Phe 244) was in the last nucleotide of exon 8. Nucleotide variants in the first or last exonic nucleotides could also affect pre-mRNA splicing and results in the premature degradation of the aberrant transcripts (25) (26) (27) . Unequal allele expression due to changes in mRNA stability was also reported for some MYH7 mutations, and could partly explain the heterogenous phenotype between HCM patients (28) . The bioinformatic analysis predicted a reduction of the splicing score for the rs2069542 minor T-allele compared to the common C-allele. To determine whether this SNP was associated with the risk of developing HCM in our population, we genotyped all the patients and controls and compared the allele and genotype frequencies between the two groups. The rs2069542-T was significantly more frequent among the patients compared to the healthy controls, suggesting that this allele could increase the risk of developing HCM in our population. However, the cDNA from heart tissue of two rs2069542 TC patients showed a normal transcript sequence with the two alleles. This suggested a lack of effect of this SNP on pre-mRNA splicing.
Upregulation of beta-MHC correlated with cardiac mass increases in ventricular hypertrophy (29) . This effect could be mediated by the overexpression of several TFs that targeted the MYH7 promoter (30) . In our screening of the MYH7-promoter region we found several nucleotide variants. Six were rare changes not found among the controls, and could thus be associated with HCM-risk through the differential binding of TFs that could regulate the expression of MYH7 and other sarcomeric genes (31, 32) .
For instance, -537 T>C was found in two patients and none of the controls. The rare Callele would create a binding site for NKX2, a TF that has been implicated in cardiac biogenesis and hypertrophy (30) . Moreover, mutations in the NKX2.5 gene have been found in patients with cardiac anomalies and atrioventricular conduction block (33) . The rare -923 rs17092354 A was found in 5 patients and only one control. This allele would create a binding site for NF-k, a TF whose silencing would prevent cardiac hypertrophy and heart failure in mice (34) . Although our data suggested that these nucleotide variants in the MYH7 promoter could be linked to the HCM-risk, functional
studies are required to demonstrate a difference on TFs-DNA binding and gene expression between the alleles. Some 3´UTR have been linked to disease risk through their differential binding to miRNAs. We found two MYH7 3´UTR variants, and the bioinformatic analysis showed that none of them would affect the binding of known miRNAs (including the c.*29T>C, found in two patients and none of the controls). Thus, a mutational mechanism based on the regulation of MYH7 expression through miRNAs binding should be unlikely.
However, we cannot rule out other mechanisms that regulate gene expression by the 3'UTR, such as mRNA editing based on secondary structure, regulatory proteins, or cleavage within repeat consensus sequences (35, 36) .
Finally, our approach to characterize the full mutational spectrum of MYH7 could also be applied to other sarcomeric genes. Exons deletion and splicing mutations in the immediately flanking intronic nucleotides have been found in the MYBPC3 and other sarcomeric genes. It is thus possible that internal intronic mutations that affected splicing were also present in these genes in some HCM patients. The full sequencing of these genes with massive next generation sequencing would help to elucidate the full mutational spectrum of sarcomeric genes in HCM. 5´GTA AAA CGA CGG CCA GT GTT TGG GAA GGG GGG GAG C 3´ 5´AAT GAT GCC GTA CGG CA TCT GCA TGG GCA TGG GGC AT 3´
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